logo-loader
AIM:SAR

Sareum Holdings PLC

Receive alerts
Market:
AIM
Market Cap:
£21.35 m
Price
0.70 GBX
Change
-8.55%
52 weeks high
1.10
52 weeks low
0.03

In brief

Sareum discovers and develops innovative drug candidates aimed at cancers and autoimmune diseases. Our drug development programmes aim to improve outcomes for patients with serious medical conditions and where current therapies are inadequate.

Sareum's most advanced development programme (Chk1) was developed in collaboration with the Institute of Cancer Research and the CRT Pioneer Fund. It is undergoing two Phase 2 clinical trials, being conducted by licence partner Sierra Oncology, with a further two trials planned. The other development programmes (TYK2/JAK1 Autoimmune, TYK2/JAK1 Cancer, Aurora+FLT3) are in preclinical development.

Deep dive We explore the investor case for growth companies

Snapshot

  • Lead drug being developed by partner Sierra Oncology
  • Encouraging preliminary efficacy data on SRA737 
  • Has other preclinical treatments - one autoimmune disease, one for cancer